SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-022493
Filing Date
2024-04-26
Accepted
2024-04-26 16:30:43
Documents
9
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20018274x1_def14a.htm DEF 14A 965254
2 logo_aquestive-reg.jpg GRAPHIC 43389
3 logo_aquestive-regx1.jpg GRAPHIC 54294
4 ny20018274x1_pvp01x2.jpg GRAPHIC 154485
5 ny20018274x1_pvp02x2.jpg GRAPHIC 158200
6 sig_danielbarber.jpg GRAPHIC 15636
7 sig_lorijbraender.jpg GRAPHIC 26060
8 ny20018274x1_pc01.jpg GRAPHIC 621264
9 ny20018274x1_pc02.jpg GRAPHIC 577469
  Complete submission text file 0001140361-24-022493.txt   3238306
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

IRS No.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38599 | Film No.: 24884371
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)